At the heart of Leukaemia Busters’ funded research is The Simon Flavell Leukaemia Research Laboratory at Southampton General Hospital. Here there has been a continuous stream of high quality research since 1991 that has led to the development of several antibody-based drugs for leukaemia and lymphoma. Leukaemia Busters’ funded doctors and scientists have successfully investigated two of these in early phase clinical trials in adults and children with leukaemia, lymphoma and myeloma.
The laboratory currently has two major laboratory-based research objectives, firstly the development of genetically engineered immunotoxins for use in clinical studies and secondly exploring ways of improving the potency of the immunotoxins.
By adopting this two pronged approach they anticipate being able to develop innovative and groundbreaking treatments that will ensure the destruction of leukaemia or lymphoma cells in the patients body without the nasty side effects associated with conventional chemotherapy.